Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 2/20 | 0.31 |
| ▸ | CRHBP | P24387 | 2/20 | 0.31 |
| ▸ | CRHR2 | Q13324 | 2/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.30 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.30 |
| ▸ | ITGAL | P20701 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9174815 | 0.83 | — | — | |
| SCHEMBL3417718 | 0.82 | SMN1; SMN2 (0.48) | LMNACRHBPCRHR2SMN1; SMN2HTT | |
| SCHEMBL323509 | 0.75 | — | — | |
| SCHEMBL103524 | 0.71 | — | — | |
| SCHEMBL2884931 | 0.70 | ABCG2 (0.52) | ABCG2PKMTSHRLMNACRHBP | |
| SCHEMBL14721950 | 0.69 | MAOA (0.38) | ABCG2TSHRLMNASMN1; SMN2ITGB2 | |
| SCHEMBL4894 | 0.68 | — | — | |
| SCHEMBL736844 | 0.68 | — | — | |
| SCHEMBL130778 | 0.68 | ITGB2 (0.39) | ABCG2LMNACRHBPCRHR2SMN1; SMN2 | |
| SCHEMBL980840 | 0.68 | MAOA (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 134 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11873309-B2 | Heterocyclic compounds as immunomodulators | INCYTE CORPORATION (US) | 2024-01-16 | — | — | US | claimed |
| US-11718605-B2 | Heterocyclic compounds as immunomodulators | INCYTE CORPORATION (US) | 2023-08-08 | — | — | US | claimed |
| CN-115925527-A | Method for preparing alpha-diaryl methyl substituted ketone compound | 湖南理工学院 | 2023-04-07 | — | — | CN | claimed |
| EP-4137489-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | Incyte Corporation (US) | 2023-02-22 | — | — | EP | claimed |
| US-20210317139-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION | 2021-10-14 | — | — | US | claimed |
| EP-3504198-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | Incyte Corporation (US) | 2019-07-03 | — | — | EP | claimed |
| EP-3484866-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | Incyte Corporation (US) | 2019-05-22 | — | — | EP | claimed |
| EP-3472167-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | Incyte Corporation (US) | 2019-04-24 | — | — | EP | claimed |
| US-20190040082-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION | 2019-02-07 | — | — | US | claimed |
| WO-2018044783-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION (US) | 2018-03-08 | — | — | WO | claimed |
| US-20030208075-A1 | Process for making chiral 1,4-disubstituted piperazines | WYETH | 2003-11-06 | — | — | US | claimed |
| US-20030187265-A1 | Process for synthesizing N-aryl piperazines with chiral N'-1-[benzoyl(2-pyridyl)amino]-2-propane substitution | WYETH | 2003-10-02 | — | — | US | claimed |
| WO-2003078417-A1 | PROCESS FOR SYNTHESIZING CHIRAL N-ARYL PIPERAZINES | WYETH, A CORPORATION OF THE STATE OF DELAWARE (US) | 2003-09-25 | — | — | WO | claimed |
| WO-2003078420-A2 | PROCESS FOR MAKING CHIRAL 1,4-DISUBSTITUTED PIPERAZINES | WYETH (US) | 2003-09-25 | — | — | WO | claimed |
| US-5869486-A | EXHIBIT INHIBITORY ACTIVITY ON CYCLIC GUANOSINE 3',5'-MONOPHOSPHATE PHOSPHODIESTERASE; ADMINISTERING TO TREAT CARDIOVASCULAR AND RESPIRATORY SYSTEM DISORDERS | ONO PHARMACEUTICAL CO., LTD. (JP) | 1999-02-09 | — | — | US | claimed |
| JP-H08512031-A | — | — | 1996-12-17 | — | — | JP | claimed |
| EP-0728759-A1 | Heterocyclic compounds | ONO PHARMACEUTICAL CO., LTD. (JP) | 1996-08-28 | — | — | EP | claimed |
| EP-0704067-A1 | PHOTOCHROMIC NAPHTHOPYRAN COMPOUNDS | PPG INDUSTRIES, INC. (US) | 1996-04-03 | — | — | EP | claimed |
| EP-0704067-A4 | PHOTOCHROMIC NAPHTHOPYRAN COMPOUNDS | PPG INDUSTRIES INC (US) | 1996-02-02 | — | — | EP | claimed |
| WO-1995000866-A1 | PHOTOCHROMIC NAPHTHOPYRAN COMPOUNDS | PPG INDUSTRIES, INC. (US) | 1995-01-05 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210317139-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | CD74, IL2, ICOS | ABCG2 1928/4885PKM 3487/4885TSHR 2482/4885 |
| US-11718605-B2 | Heterocyclic compounds as immunomodulators | CD74, IL2, ICOS | ABCG2 1928/4885PKM 3487/4885TSHR 2482/4885 |
| US-20030187265-A1 | Process for synthesizing N-aryl piperazines with chiral N'-1-[benzoyl(2-pyridyl)amino]-2-propane substitution | TPH1, HTR1B, HTR1A | ABCG2 1176/4885PKM 2143/4885TSHR 705/4885 |
| US-11873309-B2 | Heterocyclic compounds as immunomodulators | CD74, IL2, ICOS | ABCG2 1928/4885PKM 3487/4885TSHR 2482/4885 |
| US-20190040082-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | CD74, IL2, ICOS | ABCG2 1928/4885PKM 3487/4885TSHR 2482/4885 |
| US-20030208075-A1 | Process for making chiral 1,4-disubstituted piperazines | HTR1D, HTR1A, HTR5A | ABCG2 453/4885PKM 3873/4885TSHR 540/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.